http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022114810-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7b72691b61448140b9a080282c2ccf0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a74935159a0a871dd85e00c138f7fe6b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2021-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65d8405ba3a5992f0698e2ec6f800264 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af2a21e93a740d3494849fb53cdc2bf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84134b1f46d43a4fdc25ad9087b98119 |
| publicationDate | 2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022114810-A1 |
| titleOfInvention | Pharmaceutical composition, for preventing or treating fibrotic diseases, comprising progranulin protein or active fragments thereof as active ingredient |
| abstract | The present invention relates to a pharmaceutical composition and the like, for preventing or treating pulmonary or airway fibrosis, comprising a progranulin (PGRN) protein or active fragments thereof as an active ingredient. The present invention is accomplished by confirming that progranulin and active fragments thereof can effectively inhibit pulmonary and airway inflammation and fibrosis. Particularly, the present inventors injected a progranulin and active fragments (PGRN-FBAC, PGRN-BACD and PGRN-CDE) thereof to a pulmonary fibrosis animal model and, as a result, confirmed reduced infiltration of inflammatory cells into the pulmonary and airway tissues and reduced fibroblast proliferation and collagen production as well as relief in inflammation-induced tissue damage. Further, the inventors induced an inflammatory response from an epithelial cell line and pulmonary fibroblasts and treated same with progranulin and active fragments thereof and, as a result, confirmed reduced levels and activities of fibronectin, p-NFκB, COL1A1, F-actin and the like which are fibrosis markers. Since said results exhibit effects of the progranulin protein and active fragments thereof in relieving pulmonary and airway inflammation and fibrosis, the progranulin protein and active fragments thereof according to the present invention are expected to be utilized as therapeutic means for various diseases induced by pulmonary and airway fibrosis. |
| priorityDate | 2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 216.